Clinical Trials
77 trialsMK-5684-01A
Merck Sharp & Dohme LLC
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
IDeate-Prostate02
Merck Sharp & Dohme LLC
COCORIVO
Centre Henri Becquerel
QUEST
Janssen Research & Development, LLC
KLK2-PASenger
Janssen Research & Development, LLC
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
MAGNITUDE
Janssen Research & Development, LLC
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
SECuRE
Clarity Pharmaceuticals Ltd
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
AMX-500
Vir Biotechnology, Inc.
FASN
Wake Forest University Health Sciences
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
T.O.A.D. Oncology SA
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
Tamarack
MacroGenics
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
ENGAGER-PSMA-01
Janux Therapeutics
INSPIRE
Radboud University Medical Center
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Celgene
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Weill Medical College of Cornell University
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Bayer
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
LACOG 1818
Latin American Cooperative Oncology Group
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC
Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lantheus Medical Imaging
PEACE8
UNICANCER
PSMAxCD3
University Hospital Tuebingen
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
ANZadapt
Leiden University Medical Center
GUIDE
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
IMbassador250
Hoffmann-La Roche
COMRADE
Sheffield Teaching Hospitals NHS Foundation Trust
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa